ISUPREL
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
May 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISUPREL is an injectable sympathomimetic amine approved in 1956 for acute cardiac and circulatory conditions. The drug's mechanism of action involves beta-adrenergic receptor stimulation to increase heart rate and cardiac output. It is used primarily in acute care settings for hemodynamic support and cardiac arrhythmia management.
LOE Approaching
Declining product nearing loss of exclusivity with minimal commercial infrastructure; limited career growth opportunity within brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ISUPREL offers minimal career opportunity as a legacy product with zero linked job openings and approaching loss of exclusivity. Roles would focus on maintaining compliance and managing declining market presence rather than commercial growth.
Supply Chain ManagerRegulatory Affairs Specialist
Worked on ISUPREL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.